ALCJ Share Price Performance
€1.46
-0.39 (-21.08%)
Price €1.46
Share Price€1.46
ALCJ Community Narratives
There are no narratives available yet.
Recent ALCJ News & Updates
No updates
Crossject Société Anonyme Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.24
- Gross Margin
- -192.39%
- Net Profit Margin
- -310.94%
- Debt/Equity Ratio
- -788.2%
Crossject Société Anonyme Competitors
About ALCJ
- Founded
- 2001
- Employees
- 102
- CEO
- WebsiteView website
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, a needle-free device for patient-side management disorders self-injectables. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. The company was founded in 2001 and is based in Dijon, France.
French Market Performance
- 7 Days: -2.8%
- 3 Months: -1.5%
- 1 Year: 3.5%
- Year to Date: 1.6%
Over the last 7 days, the market has dropped 2.8%, driven by a decline of 5.3% in the Consumer Discretionary sector. In the last year, the market is actually up 3.5%. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading